To view this email as a web page, click here.
 
How FDA’s insomnia drug warning could affect prescribing
Stronger warnings on popular insomnia medications could have an impact on prescribing, some experts say.
Read more
 
New RA biosimilar impact hinges on patent lawsuit
While FDA approved the second biosimilar drug to Enbrel, the success of the medication hinges on a pending lawsuit.
Read more
 
Calls for “structural policy changes” for biosimilars market
From our sister brand, Managed Healthcare Executive: A new report lays out a policy roadmap, based on European successes, to help increase access to and development of biosimilar treatments.
Read more
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.